Study identifier:D8480C00030
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of Cediranib 45mg Versus Placebo following 12 Weeks of Treatment in Patients with Metastatic or Recurrent Renal Cell Carcinoma who have had no Previous Anti-VEGF Therapy.
Renal Cell Carcinoma
Phase 2
No
Cediranib, Cediranib Placebo
All
105
Interventional
18 Years - 99 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2016 by AstraZeneca
AstraZeneca
-
Cediranib is being tested to assess its effectiveness on the growth of kidney cancer tumours and also how well it is tolerated.
Location
Location
Birmingham, United Kingdom
Location
London, United Kingdom
Location
Manchester, United Kingdom
Location
Northwood, United Kingdom
Location
Oxford, United Kingdom
Location
NIJMEGEN, Netherlands
Location
Groningen, Netherlands
Location
LEIDEN, Netherlands
Arms | Assigned Interventions |
---|---|
Placebo Comparator: 1 Cediranib placebo | Drug: Cediranib Placebo oral tablet |
Experimental: 2 Cediranib | Drug: Cediranib 45 mg oral tablet Other Name: AZD2171 Other Name: RECENTIN™ |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.